Skip to main content
Toni Choueiri, MD, Oncology, Boston, MA, Brigham and Women's Hospital

ToniKChoueiriMD

Oncology • Boston, MA

Genitourinary Oncology, Hematologic Oncology

Director, Lank Center for Genitourinary Oncology; Director, Kidney Cancer Center, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, Harvard Medical School (@DrChoueiri)

Join to view full profile

Dr. Choueiri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Choueiri's full profile

Already have an account?

Summary

  • Dr. Toni Choueiri is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dana-Farber Cancer Institute. He received his medical degree from St Joseph's University Medical School and has been in practice 17 years. He also speaks multiple languages, including Arabic and French. He specializes in genitourinary oncology (kidney, prostate, bladder and testicular cancers). He is a Professor of Medicine at Harvard Medical School.

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
  • St Joseph's University Medical School
    St Joseph's University Medical SchoolClass of 2000

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2006 - 2025
  • RI State Medical License
    RI State Medical License 2020 - 2020
  • OH State Medical License
    OH State Medical License 2001 - 2011

Awards, Honors, & Recognition

  • Schonfeld Award Kidney Cancer Association, 2016
  • George Canellos Award for Excellence in Clinical Investigation Dana-Farber Cancer Institute, 2013
  • Most Compassionate Doctor American Registry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma  
    Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
  • Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic  
    Toni Choueiri, MD, JAMA Oncology
  • Rethinking Clinical Trials Reform During the COVID-19 Pandemic  
    Chadi Nabhan, Toni K Choueiri, JAMA Oncology
  • Join now to see all

Lectures

  • Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell ca... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Authored Content

  • Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
  • Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Efficacy of Savolitinib vs Sunitinib in Patients with MET-Driven Papillary Renal Cell CarcinomaMay 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
  • Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
  • Clinical and Genomic Characterization of Low–Prostate-Specific Antigen, High-Grade Prostate CancerFebruary 2018
  • Comparative Effectiveness of Robot-Assisted vs. Open Radical Cystectomy☆☆☆December 2017
  • Join now to see all

Press Mentions

  • Phase 3 Studies for Rectal, Brain, and Kidney Cancers to Be Presented by Dana-Farber Researchers at ASCO 2023
    Phase 3 Studies for Rectal, Brain, and Kidney Cancers to Be Presented by Dana-Farber Researchers at ASCO 2023May 26th, 2023
  • Three-Drug Combination Slows Progression of Advanced Kidney Cancer
    Three-Drug Combination Slows Progression of Advanced Kidney CancerMay 11th, 2023
  • These Microbes Found in Tumours Promote Cancer. What if We Just Kill Them?
    These Microbes Found in Tumours Promote Cancer. What if We Just Kill Them?April 21st, 2023
  • Join now to see all

Professional Memberships

Other Languages

  • Arabic, French

Hospital Affiliations

Dr. Toni Choueiri, Dr. Toni Choueiri, MD, Dr. T Choueiri, Dr. Toni K Choueiri